Curatis Holding AGXSWX:CURN +3.51%33 EBIT per Share is CHF-0.30 as of Dec. 2025. GuruFocus rates XSWX:CURN with a GF Score™ of 33/100. The stock has 7 warning signs investors should review. Among 811 Drug Manufacturers companies, Curatis Holding AG ranks better than 95.31% on this metric.
Curatis Holding AG's EBIT per Share for the
six
months ended in Dec. 2025 was CHF-0.04.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-0.30.
During the past 3 years, the average EBIT per Share Growth Rate was 70.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Curatis Holding AG's EBIT per Share or its related term are showing as below:
XSWX:CURN'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 53.4 Med: 61.8 Max: 70.2
Current: 70.2
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Curatis Holding AG was 70.20% per year. The lowest was 53.40% per year. And the median was 61.80% per year.
XSWX:CURN's 3-Year EBIT Growth Rate is ranked better than 95.31% of 811
companies
in the Drug Manufacturers industry
Industry Median: 7.8
vs XSWX:CURN: 70.20
Curatis Holding AG (XSWX:CURN) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Curatis Holding AG EBIT per Share Related Terms
Curatis Holding AG EBIT per Share Historical Data
* Premium members only.
The historical data trend for Curatis Holding AG's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-0.30
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curatis Holding AG (XSWX:CURN) has a EBIT per Share of CHF-0.30 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Curatis Holding AG and its competitors. According to the industry distribution chart, Curatis Holding AG ranks #38 out of 811 companies in the Drug Manufacturers industry, placing it in the top 4.7%.
Is Curatis Holding AG's EBIT per Share too high?
Curatis Holding AG's current EBIT per Share is CHF-0.30. Based on the distribution chart, Curatis Holding AG ranks #38 out of 811 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Curatis Holding AG has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Curatis Holding AG's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curatis Holding AG ranks #38 out of 811 companies for EBIT per Share. This places Curatis Holding AG in the top 5% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Curatis Holding AG and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curatis Holding AG's current EBIT per Share is CHF-0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curatis Holding AG stock overvalued right now?
Curatis Holding AG (XSWX:CURN) has a current EBIT per Share of CHF-0.30. The current EBIT per Share is CHF-0.30. Curatis Holding AG's overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Curatis Holding AG (XSWX:CURN), the current EBIT per Share is CHF-0.30 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curatis Holding AG is a specialty pharmaceutical Company with two-pillar. On one hand, the Company trades and distributes specialty medicines in the rare disease and specialty medicines space i.e. acquires, licenses, distributes and promotes pharmaceutical products for the treatment and/or prevention of rare and specialty diseases in Switzerland. On the other hand, it is a drug development Company with a pipeline of product candidates, also predominantly in the orphan drug space.
33GF Score
Get the complete analysis for XSWX:CURN
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:CURN has been successfully added to your 
